Video

Clinical Trials For My Patients - Kidney Cancer VL

Search

The RadiCaL Study: Enhancing Cabozantinib with Radium-223 Dichloride for Advanced Renal Cell Cancer with Bone Metastasis (RadiCal) Details The RadiCaL trial is comparing the effectiveness of cabozantinib alone versus cabozantinib combined with radium-223 in metastatic renal cell cancer patients. This phase II trial investigates if the addition of radium-223 to the standard treatment, cabozantinib, improves outcomes in patients with bone metastases. Radium-223 is a radioactive drug that can target cancer cells directly while minimizin...
The Benefit to Radium-223 Added to Cabozantinib for Patients With Renal Cell Carcinoma With Bone Metastasis, RadiCaL - Rana McKay Details Rana McKay joins Alicia Morgans to discuss the RadiCaL trial, a study looking at metastatic kidney cancer and the use of radium in that population. The trial is a phase II trial, taking patients with renal cell carcinoma (RCC) with bone metastases and randomizing them 1:1 to receive radium with cabozantinib versus cabozantinib alone. The primary endpoint of RadiCaL is a reduction in symptomatic sk...
The PDIGREE Trial - Define Rational Sequencing in Combination Treatment of mRCC - Tian Zhang Details Principal investigator Tian Zhang joins Alicia Morgans to discuss the recent progress of the currently enrolling PDIGREE (Alliance A031704) trial. PDIGREE: An Adaptive Phase III Trial of PD-Inhibitor Nivolumab and Ipilimumab with VEGF TKI Cabozantinib in Metastatic Untreated Renal Cell Cancer (Alliance A031704) has been open since May of 2019 and now has nearly 300 patients enrolled, many of whom...
The Alliance Trial A031801 - RadiCal a Trial of Radium-223 in Patients with Renal Cell Carcinoma, - Rana McKay Details Potentially practice-changing study sponsored by the National Cancer Institute — A discussion with Rana McKay, MD, principal investigator. Radium-223 (223Ra) is an alpha particle-emitting radioactive agent that received Federal Drug Administration (FDA) approval in 2013 to treat patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic diseas...
PDIGREE: An adaptive phase III trial of PD-inhibitor Nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI Cabozantinib (CABO) in Metastatic Untreated RCC (Alliance A031704). -Tian Zhang Details PDIGREE is a novel adaptive frontline immunotherapy study which upon completion will help answer many important questions regarding treatment duration, when to combine VEGF therapy with IO therapy, and which patients benefit most from IO-VEGF combination upfront vs. sequential therapy. This trial is actively enrolling patients at all National Clinical Trials Network (NCTN) study sites. The primary...